Adagene Inc. (NASDAQ: ADAG) reported updated data from its Phase 1b/2 study showing muzastotug combined with pembrolizumab achieved a 31 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE